Systemic Lupus Clinical Trial
Official title:
Study of the Immune Response to SARS-CoV-2 Vaccination in Patients With Systemic Lupus
The main objective is to study the impact of vaccination against Covid-19 on the specific humoral and cellular immune response (against SARS-CoV-2) and non-specific (evolution of the pathological immune system of the disease), in a lupus population. The secondary objective is to study the impact of lupus disease activity on the humoral and cellular response of patients following vaccination against SARS-CoV-2. The hypothesis is that disease activity and / or certain treatments used in lupus may interfere with the humoral and cellular immune response induced by vaccination against SARS-CoV-2.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03749044 -
ASA Patterns for Prevention of Preeclampsia in SLE Pregnancies
|
N/A | |
Completed |
NCT03218033 -
Use of Social Media to Improve Medication Adherence in Adolescents and Young Adults With Systemic Lupus
|
N/A | |
Not yet recruiting |
NCT03752983 -
Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE
|
||
Recruiting |
NCT03819777 -
Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)
|
||
Not yet recruiting |
NCT03164720 -
SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis
|
||
Completed |
NCT03762824 -
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease
|
Phase 4 | |
Not yet recruiting |
NCT06435468 -
Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases
|
N/A | |
Terminated |
NCT01738360 -
Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)
|
Phase 2 | |
Completed |
NCT03430388 -
Yellow Fever Vaccine in Patients With Rheumatic Diseases
|
N/A | |
Completed |
NCT04108611 -
Immune Adsorption Role in Treatment of Resistant Lupus
|
N/A | |
Not yet recruiting |
NCT04256577 -
Serum Ceramides Level in Systemic Lupus Erythematosus (SLE) Patients as a Novel Marker for Renal Impairment
|
||
Completed |
NCT03540823 -
Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases
|
Phase 4 |